Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent

After a turbulent couple of years, Ovid is officially doing away with a program it had once championed in the face of heavy analyst skepticism …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ovid cuts its loss­es on con­tro­ver­sial An­gel­man syn­drome drug, mak­ing its crush­ing de­vel­op­ment halt per­ma­nent